On-Body Device Simplifies Isatuximab Cancer Treatment
Patients with cancer may soon experience faster isatuximab delivery through a new on-body device that requires less constant monitoring.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Do you believe wearable medical devices make your healthcare routine more manageable and efficient?
Clinical trials are evaluating an on-body delivery system for the cancer treatment isatuximab, which aims to improve the administration process. More than 70% of patients who participated in the studies preferred the new device over traditional delivery methods.
Why it matters
This innovation streamlines care by reducing the time nurses spend monitoring each dose, potentially improving patient flow at high-volume clinics. For patients, the shift aims to enhance the overall experience and treatment tolerance.
In trials including IZALCO (NCT05704049) and IRAKLIA (NCT05405166), researchers evaluated patient preference for an on-body device compared to traditional subcutaneous administration. Over 70% of patients reported preferring the new device, which utilizes a smaller 31-gauge needle.
The players
IZALCO
A clinical trial registered under NCT05704049 evaluating delivery methods for isatuximab.
IRAKLIA
A clinical trial registered under NCT05405166 investigating novel administration techniques for monoclonal antibody treatments.
The details
The new device simplifies the administration process by allowing nurses to press a single button to initiate treatment, after which they can leave the patient until the device signals completion. Unlike traditional subcutaneous delivery, which requires a nurse to remain present for 20 minutes, the first on-body dose requires no such extended monitoring. By using a 31-gauge needle rather than the standard 24-gauge, the system also aims to improve patient comfort.
Health Landscape
This development follows an industry-wide trend toward optimizing the administration of monoclonal antibodies, such as those targeting CD38. It marks a departure from traditional, labor-intensive infusion and injection protocols that currently occupy nurses for 20 to 25 doses daily.
Patients receiving CD38-targeted therapies should discuss potential changes to their treatment delivery protocols with their oncologist. This technology may impact time spent at infusion centers, so asking if your care team uses or plans to adopt on-body delivery devices is a helpful conversation starter.
The takeaway
The on-body delivery device aims to save significant clinical time while enhancing patient comfort during cancer therapy. Talk to your healthcare provider to understand how new administration technologies may fit into your existing treatment plan.
Further reading
For more information on current treatment standards and emerging clinical research, visit Cancer.
Live Poll
Do you believe wearable medical devices make your healthcare routine more manageable and efficient?
